Sensai
Reading the tape…Pulling live market data…Setting the scene…
Sensai
AI Stock Dissection
AI Stock Dissection
ERIS
Mr. Amit Indubhushan Bakshi · Ahmedabad, India
₹1,426.50
▲+2.57%ERIS (ERIS.NS) is trading near its 52-week high due to strong growth in revenue and earnings, despite relatively high debt levels.
Exchange
NSI
Currency
INR
Day range
₹1,383.90 – ₹1,441.90
52-week range
₹1,200.00 – ₹1,885.00
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
AI investment rating
AI analysis60% confidence
Current price is trading near the upper third of its 1-year range, suggesting a neutral valuation view, however high growth in revenue and earnings supports a slight premium valuation.
24.3% below the 1-year high · trend up
Hedge-fund memo
Today
Prices rose 2.57% today on moderate trade volume, no clear catalyst.
This week
Continues to trade within its 52-week high-low range.
This month
Month-to-date change not provided, but has generally moved higher recently.
Bull thesis
Bear thesis
Hidden risks
Hidden opportunities
News & sentiment
Bullish
20 headlines · 15 outlets · 7d
Tone · daily average
Smart money
Named holders aren't published for this listing (common for Indian stocks). The split at left is live.
Financial health
Profitability
Growth
Balance sheet
Financial statements
Earnings intelligence
Beat estimates in 1 of 4 recent quarters (EPS actual vs. consensus).
20.57 vs 8.66667
137.35% surprise
8.2563 vs 9.05
-8.77% surprise
8.81 vs 9.2
-4.24% surprise
Competitive landscape
| Company | Market cap | P/E | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| ERIS | 197.68B | 31.56 | 18.07% | 27.12% | 7.10% |
| JBCHEPHARM | 387.93B | 54.22 | 18.69% | 16.48% | -4.80% |
| ALKEM | 678.23B | 29.43 |
Technical intelligence
Volume
RSI (14) · 70 overbought / 30 oversold
MACD (12,26,9) · MACD vs signal
Candlesticks, volume, RSI and MACD from 498sessions of real Yahoo daily data. Moving averages use full history, so they're accurate at the left edge. Support / resistance are the 52-week low / high. Educational — technical signals are not buy or sell calls.
Risk intelligence
Increased competition from generic and specialty drug manufacturers
Mitigation: Maintain a diversified portfolio to minimize sector-specific risks
Regulatory changes affecting market access and pricing
Mitigation: Monitor government policies and adjust the portfolio accordingly
Business intelligence
Competitive moat
ERIS's product offerings have strong market competition, limiting the potential for sustained competitive advantage, although its strong market presence and operational efficiency provide a temporary barrier.
Supply chain
Upstream (inputs / suppliers)
↓
Downstream (customers / markets)
M&A / strategic moves
No notable recent activity flagged.
Catalyst calendar
Release of quarterly results
Announcement of market expansion plans
Thesis builder
Bull case
Eris could sustain its growth momentum in the near term
Base case
Short-term growth could slow due to high debt levels and increased competition
Bear case
Eris may struggle to maintain its market share and profitability in a highly competitive sector
Time horizon
Short to medium term (6-24 months)
Est. CAGR
15-20%
Entry (qual.)
Consider adding to a core portfolio, looking for a pullback to 1300-1350 INR
Exit (qual.)
Sell on a close above 1500 INR, indicating potential for sustained outperformance
Overall conviction 60%
Knowledge graph
Executives & sector are live; peers are clickable → their dissection. Institutional holders shown where the exchange publishes them.
Portfolio impact
Enter tickers + weights, then see how ERIS fits.
Scenario simulator
Simulate a macro shock and see the illustrative impact:
Tailwind for tech & enablers.
Illustrative impact
Medium prob.Directional illustration only — not modelled on this company's actuals. A real simulator needs company financials.
Explain like…
Re-explain ERIS for a different audience:
Pick a persona to get a tailored explanation.
Sensai publishes educational market commentary, not investment advice. We are not SEBI-registered investment advisers or research analysts, and nothing here is a recommendation to buy, sell, or hold any security.
Live prices, index levels, and other market data are pulled from third-party feeds, may be delayed, and can be inaccurate or unavailable. Do not rely on them for trading decisions.
Investing in equities carries risk, including the loss of principal. Always do your own research and consider consulting a SEBI-registered adviser before making any investment decision.
Watch next
Monitor the company's ability to sustain and grow its profitability
Investing.com·2h ago·large multi-year AI deal
Investing.com UK·3h ago·Q1 earnings growth reported
Whalesbook·4h ago·Q1 PAT increases significantly
Whalesbook·4h ago·pressure on margins
Moneycontrol.com·4h ago·strong domestic formulations growth reported
CNBC TV18·4h ago·Q1 profit jumps 21%
Business Standard·6h ago·Q1 PAT climbs 21% YoY
TradingView·6h ago·robust revenue and profit growth reported
Sahi·7h ago·Q1 consolidated net profit rises 16% YoY
TradingView·7h ago·revenue and PAT growth led by DBF and GLP-1 market gains
scanx.trade·7h ago·revenue rises 13% YoY
Business Upturn·7h ago·14.5% growth in Q1 PAT reported
Whalesbook·7h ago·₹143 cr mुनाफा declared, ₹7.21 dividend reported
Radio Times·2d ago·Irrelevant, unrelated to ERIS business
TradingView·2d ago·Financial data on a different ERIS company
Tribuna.com·3d ago·Athlete stats unrelated to ERIS business
TradingView·3d ago·Q1 revenue and breakdown provided
Transfermarkt·5d ago·Person's name, not a business news article
Barchart.com·5d ago·Financial data on a different ERIS product
The Economic Times·6d ago·Stock crosses below 200 DMA, negative signal for ERIS stock, but not business outlook
Real press coverage from the last 7 days, scored by AI for tone — click any headline for the source. This is news sentiment, not social: X / Reddit / Telegram scoring needs a paid social provider. Educational only.
Annual income statement, oldest → newest. Live via Yahoo.
8.64 vs 8.73333
-1.07% surprise
| 17.56% |
| 11.42% |
| 14.60% |
| CAPLIPOINT | 198.63B | 31.07 | 19.94% | 30.90% | 19.00% |
Peers via Yahoo's similarity graph, same-sector first; fundamentals live. Ask the AI copilot below for a qualitative head-to-head.
Support (day/52w low)
₹1,383.90
Resistance (day/52w high)
₹1,441.90
Volume
3,69,152
Trend
up
RSI (14)
49
MACD
bearish
MA cross
death
50-day MA
₹1,413.61
200-day MA
₹1,445.19
vs 200-DMA
-1.3%
RSI/MACD computed from 6 months of daily closes; moving averages from Yahoo. Options positioning still needs an options feed.